Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lym-1
- Development stage
- Unknown
- Lead developer
- UC Davis Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lym-1 is a murine IgG2a monoclonal antibody that specifically targets the HLA-DR10 protein, a cell surface marker present on over 80% of lymphoma cells. Developed in the early 1980s by immunizing mice with nuclei from Raji lymphoma cells, it binds to a conformational epitope on several HLA-DR subtypes with higher affinity for malignant B cells than normal B cells. The antibody has been used as an unconjugated agent and as a radioimmunoconjugate labeled with isotopes such as iodine‑131 (131I) or copper‑67 (67Cu) for radioimmunotherapy of chemotherapy-resistant non-Hodgkin lymphoma and other B-cell malignancies. Clinical trials have demonstrated tumor regression and durable remissions in patients with refractory disease. Mechanistically, when bound to its target epitope, Lym‑1 can induce apoptosis or autophagy in target cells and mediate cytotoxicity through ADCC or CDC[3][4][7][9].
- Brand names
- Oncolym
- Other names
- monoclonal antibody Lym-1murine MAb (Lym-1)Iodine I 131 Lym-1 Monoclonal Antibody131I-Lym-167Cu-2IT-BAT-Lym-1
02
Targets
HLA-DRβ (HLA-DR beta chain)
Beyond the preview
Go deeper on Lym-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lym-1.